RxDoctor Payments Data

Amy Boone

Family · Greer, SCNPI 1740467281

Payments from drug & device makers

$7,153in general payments, 2019–2025

Across 392 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Ardelyx, Inc.$502
  • Johnson & Johnson$490
  • Pfizer$452
  • Takeda Pharmaceuticals U.S.A., Inc.$365
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$7,07699%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,153 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$30,746
Medicare patients
218
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide55$38,812
CreonLipase/Protease/Amylase17$33,216
MotegrityPrucalopride Succinate17$8,544
Dexlansoprazole DrDexlansoprazole11$3,545
Lubiprostone30$3,271
Pantoprazole Sodium168$1,479
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg70$1,437
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,185
CholestyramineCholestyramine (With Sugar)15$605
Omeprazole61$490
Famotidine36$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,094$72,02972 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$365$8,54417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →